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PHeart Failure
ommunity Screening for Left
entricular Systolic Dysfunction Using
lasma and Urinary Natriuretic Peptides
eong L. Ng, MD,* Ian W. Loke, MB,* Joan E. Davies, PHD,*‡ Sandeep Geeranavar, BSC,*
amlesh Khunti, MD,† Margaret A. Stone, PHD,† Derek T. Chin, MB,‡ Iain B. Squire, MD*
eicester, United Kingdom
OBJECTIVES We sought to compare urinary and plasma N-terminal pro-brain natriuretic peptide
(N-BNP) in left ventricular systolic dysfunction (LVSD) diagnosis.
BACKGROUND Plasma N-BNP is elevated in LVSD. Renal tubule cells produce BNP. We tested the
incremental value of urinary N-BNP in LVSD diagnosis.
METHODS In this prospective, community-screening study of undiagnosed LVSD, 1,360 subjects (45 to
80 years of age) were invited, and 1,308 had analyzable echocardiographic scans and urine and
plasma specimens. The criterion standard for LVSD was defined as a wall motion score over
1.8 (ejection fraction 40%).
RESULTS Twenty-eight patients with LVSD had elevated urinary and plasma N-BNP levels compared
with normal subjects (p  0.0005). Receiver-operating characteristic (ROC) areas under the
curve (AUCs) for urinary and plasma N-BNP were 0.831 and 0.840, respectively. Both tests
had high negative predictive values (99%) for excluding LVSD. Urinary N-BNP was more
specific (67.2%) than plasma N-BNP (41%). The plasma/urinary N-BNP product yielded a
higher ROC-AUC (0.923) and specificity (78%), reducing the number of cases to scan to
detect one case of LVSD to 11.4 (compared with 16.6 [urinary N-BNP] and 29.0 [plasma
N-BNP]). Sequential application of tests (urinary N-BNP, then plasma N-BNP in the
urine-“positive” cases) achieved similar reductions in the number of cases to scan (10.8), while
limiting the number of N-BNP tests to be performed. Urinary N-BNP performed poorly in
detection of other cardiac abnormalities with preserved systolic function. It was less costly to
test urinary N-BNP in the whole population as compared with other strategies, including
scanning high-risk cases with N-BNP testing in the remainder.
CONCLUSIONS Urinary N-BNP used together with plasma N-BNP could reduce the echocardiographic
burden in screening programs. (J Am Coll Cardiol 2005;45:1043–50) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.058American College of Cardiology Foundation
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peft ventricular systolic dysfunction (LVSD) is increasingly
ommon in elderly populations and is often asymptomatic.
hese features support screening for LVSD. Although
chocardiography is the criterion standard for diagnosis of
VSD, inadequate access to primary care physicians and
xpense have limited its application to screening.
Plasma natriuretic peptides, especially the B-type pep-
ides, are elevated in LVSD (1–3). Both B-type natriuretic
eptide (BNP) and its N-terminal precursor (N-BNP) have
een utilized for LVSD exclusion due to their high negative
redictive values (NPV). Recent guidelines in Europe and
he U.S. have supported this use of plasma BNPs (4,5).
We recently reported the detection of N-BNP in urine of
atients with LVSD (6). B-type natriuretic peptide is
ynthesized in renal tubule cells (7), so that urine levels may
From the *Department of Cardiovascular Sciences and †Department of Health
ciences, University of Leicester, and ‡Department of Cardiology, Glenfield Hospi-
al, Leicester, United Kingdom. Dr. Ng has submitted patents on behalf of the
niversity of Leicester on diagnostic use of natriuretic peptides. This study is
upported by the National Health Service (NHS) New and Emerging Applications of
echnology Program.S
Manuscript received May 17, 2004; revised manuscript received November 25,
004, accepted December 10, 2004.eflect renal synthesis, as well as filtered peptide. Ease of
rine, as opposed to plasma sampling, would facilitate
ommunity screening. We therefore compared the perfor-
ance of plasma and urinary N-BNP in the detection of
ndiagnosed LVSD in a prospective, community study.
ETHODS
ecruitment. Randomly selected men (45 to 80 years of
ge) and women (55 to 80 years of age) from 21 general
ractices (stratified by list size and deprivation) in the
ormer Leicestershire Health Authority area (population
1 million) were invited for screening (between September
999 and May 2002). Excluded were subjects with a
revious diagnosis of LVSD or heart failure and those for
hom screening was considered inappropriate (e.g., house-
ound or terminally ill patients). The study was approved by
he Leicestershire Research Ethics Committee.
chocardiography. Patients underwent echocardiography
nd blood and urine sampling. Transthoracic echocardiog-
aphy was performed by one operator (I.W.L.) in all
atients using a Sonos 5500 instrument (Philips Medical
ystems, Reigate, Surrey, United Kingdom). A 16-segment
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Screening for Heart Failure Using Urine N-BNP April 5, 2005:1043–50all motion index (LVWMI) based on the American
ociety of Echocardiography model was calculated as de-
cribed (3), and those with a LVWMI score of 1.8
equivalent to a left ventricular ejection fraction (LVEF) of
0%) (3) were considered to have LVSD.
aboratory methods. Twenty milliliters of venous blood or
rine was collected into pre-chilled Na-EDTA tubes con-
aining aprotinin. Unextracted plasma and urine were as-
ayed for N-BNP using a noncompetitive immunolumino-
etric assay, as described (3,6). Urinary creatinine was
uantified by the Jaffe reaction (6).
tability of N-BNP in urine. Urinary N-BNP was mea-
ured in specimens where the urine was frozen immediately,
Abbreviations and Acronyms
AF  atrial fibrillation
AUC  area under the curve
IHD  ischemic heart disease
LVSD  left ventricular systolic dysfunction
LVWMI  left ventricular wall motion index
N-BNP  N-terminal pro-brain natriuretic peptide
NPV  negative predictive value
PPV  positive predictive value
ROC  receiver-operating characteristic
able 1. Study Population Characteristics (n  1,308)
All
en/women 742/566 (56.7/43
ge (yrs), mean (range) 63 (45 to 80)
ractice Jarman score, mean (range) 6.96 (16.0 to 41
ody mass index (kg/m2) 26.7  4.4
ystolic blood pressure 135  19
iastolic blood pressure 78  12
urrent smoker 254 (19.4)
lasma creatinine 89.5  30.3
reatinine clearance (ml/min) 77.8  22.4
edical history
Myocardial infarction 32 (2.4)
Angina 90 (6.9)
Hypertension 310 (23.7)
Diabetes mellitus 63 (4.8)
ther cardiac abnormalities
AF 16
ECG LVH 118
Valvular abnormalities* 9
rescribed therapy
ACE inhibitor/ARB 115 (8.8)
Loop diuretic 36 (2.7)
Other diuretic 165 (12.6)
Beta-blocker 147 (11.2)
Nitrate 51 (3.9)
Calcium channel blocker 128 (9.8)
atriuretic peptides, median (range)
Plasma N-BNP (fmol/ml) 44.5 (5.7 to 1,230.
Urinary N-BNP (fmol/ml) 0.54 (0.54 to 1,103
Urinary N-BNP/creatinine (fmol/mg) 3.04 (0.14 to 17,40
ata are presented as the number (%) of patients or mean value  SD, unless specifie
tenosis. p values for comparisons between LVSD and no LVSD groups: †p  0.05ACE angiotensin-converting enzyme; AF atrial fibrillation; ARB angiotensin rece
left ventricular systolic dysfunction; N-BNP  N-terminal pro-brain natriuretic peptideompared with the same specimens left at room temperature
or 24, 48, and 72 h.
ost of different screening strategies. These are based on
osts reported by Heidenreich et al. (8), who performed a
ost-effectiveness study of the use of plasma BNP in
creening for LVSD. Echocardiographic scans, plasma BNP
ests, and electrocardiograms (ECGs) cost $420, $32, and
30, respectively.
tatistical analysis. Statistical analysis was performed us-
ng SPSS Version 11.0 (SPSS Inc., Chicago, Illinois). The
eceiver-operating characteristic (ROC) areas under the
urve (AUCs) and their associated 95% confidence intervals
ere estimated. Binary logistic regression analysis was
erformed with SPSS with the stated variables, including a
onstant in the model and probability for entry or removal
et at p  0.05 and p  0.10, respectively.
ESULTS
creening invitations were accepted by 1,360 of 2,392
atients approached. The number of participants with an
nalyzable echocardiogram and available simultaneous
lood and urine samples was 1,308 (Table 1). The 28
ubjects with LVSD as defined earlier (LVWMI 1.8 or
VEF 40%) had elevated plasma N-BNP and urinary
No LVSD LVSD
720/560 (56.2/41.7) 22/6 (78.6/21.4)†
63 (45 to 80) 68 (51 to 80)‡
6.92 (16.0 to 41.4) 8.51 (10.9 to 41.4)
26.7  4.4 27.2  5.3
135  19 138  19
78  12 79  14
247 (19.3) 7 (25)
89.3  30.5 99.9  18.3§
77.9  22.4 71.4  21.6
26 (2.0) 6 (21.4)
82 (6.4) 8 (28.6)¶
302 (23.6) 8 (28.6)
61 (4.8) 2 (7.1)
14 2
115 3
8 1
109 (8.5) 6 (21.4)†
34 (2.7) 2 (7.1)
163 (12.7) 2 (7.1)
143 (11.2) 4 (14.3)
44 (3.4) 7 (25)¶
122 (3.4) 6 (21.4)†
42.2 (5.7 to 1,166.4) 360.3 (5.7 to 1,230.2)§
0.54 (0.54 to 1,103.8) 69.3 (10.8 to 839.9)§
2.87 (0.14 to 17,407) 136.2 (7.0 to 4,275.7)§
rwise. *Valvular abnormalities include moderate/severe mitral regurgitation or aortic
p  0.001 (chi-square test); ‡p  0.005 and §p  0.001 (Mann-Whitney test)..3)
.4)
2)
.8)
7)
d othe
and ¶ptor blocker; ECG LVH electrocardiographic left ventricular hypertrophy; LVSD
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April 5, 2005:1043–50 Screening for Heart Failure Using Urine N-BNP-BNP, whether or not corrected for creatinine, compared
ith normal subjects (Table 1). The LVSD group was older
nd had more males (Table 1).
In the 1,280 normal subjects, there was no significant
orrelation between plasma and urinary N-BNP (rs 
0.02). On stratification of plasma N-BNP into quartiles,
here were no significant differences in urinary N-BNP
evels. Although plasma N-BNP rose with age (rs  0.41,
 0.0005), urinary N-BNP fell with age (rs0.08, p
.005). Plasma N-BNP was correlated with creatinine
learance (rs  0.357, p  0.005), but urinary N-BNP
as not (rs0.052, p NS). The calculated filtered load
f N-BNP was not related to the measured urinary N-BNP
rs  0.031, p  NS). Unlike plasma N-BNP, urinary
-BNP was not dependent on heart rate (rs  0.01, p 
S) or gender (plasma N-BNP: male 24.8 [5.7 to 1,155] vs.
emale 72.7 [5.7 to 1,166] fmol/ml; p  0.0005); urinary
-BNP: male 0.5 [0.5 to 785] vs. female 0.5 [0.5 to 1,103]
mol/ml; p  NS). The ROC-AUCs (Fig. 1 and Table 2)
howed both plasma and urinary N-BNP to be as effective
n excluding LVSD, irrespective of correction for urinary
reatinine. Although both urinary and plasma N-BNP have
NPV, the specificity and positive predictive value (PPV) of
rinary N-BNP were higher than those of plasma N-BNP.
ence, the number of subjects needed to scan to detect one
ase of LVSD is lower with urine than with plasma N-BNP
esting (Table 2).
Ejection fractions were available from 1,037 subjects, 29
f whom had values under 40%. The ROC-AUCs for
etection of ejection fraction 40% using plasma and urine
-BNP were 0.830 and 0.833, respectively. These values
esemble those for detecting a LVWMI 1.8 for the whole
opulation (Table 2).
A history suggestive of heart failure (e.g., dyspnea or
igure 1. The receiver-operating characteristic curves for plasma and
rinary N-terminal pro-brain natriuretic peptide (N-BNP) and the plasma/
rinary N-BNP product in left ventricular systolic dysfunction detection.
olid line  urinary N-BNP; dotted line  urinary  plasma N-BNP;
ashed line  plasma N-BNP.xercise intolerance) was not useful in diagnosing LVSD Ta
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Screening for Heart Failure Using Urine N-BNP April 5, 2005:1043–50ROC-AUC 0.59). Sensitivity was poor at 32.1%, although
he specificity was 89.7%.
egression analysis. Variables included in binary logistic
egression analysis for LVSD are reported in Table 3.
ndependent predictive factors for LVSD included plasma
-BNP, urinary N-BNP, and male gender, accounting for
1.4% of the variance (Nagelkerke r2, p  0.0005). The
OC-AUC plotted from the calculated probabilities of the
odel, associated specificity, sensitivity, PPV, and NPV are
eported in Table 2. Variables in logistic regression equa-
ions are multiplied to calculate loge(odds ratio). The
roduct of the urinary and plasma N-BNP level was thus
xamined (Fig. 1 and Table 2) as a simplified LVSD
redictor. Both the logistic model and this product yielded
igher specificity and PPV for detection of LVSD than
ither plasma N-BNP or urinary N-BNP considered alone,
hile maintaining a high NPV, hence effectively reducing
he number of subjects needed to scan in order to detect one
ase of LVSD.
pplication of sequential tests. We sought to minimize
he number of N-BNP tests needed for LVSD detection.
he higher specificity of urinary N-BNP suggested its use
s a first-line LVSD screening test. In order to detect 100%
f the cases, the cut-off level for urinary N-BNP was
etermined from ROC curves to be 10.7 fmol/ml. A total of
90 subjects had a positive urinary N-BNP test, including
ll 28 LVSD subjects. There was no significant correlation
etween plasma and urinary N-BNP in the subjects with or
ithout LVSD (rs 0.002 and 0.283, respectively; pNS)
Fig. 2). Plasma N-BNP was elevated in LVSD subjects
360.3 [5.7 to 1,230] vs. 45.4 [5.7 to 1,166] fmol/ml, p 
.0005). The ROC-AUC for these urine-positive cases was
.834 (Table 2), with PPV and the number of cases needed
o scan to detect one case of LVSD very similar to that in
he logistic model or plasma/urinary N-BNP product for all
ubjects. Only one subject with LVSD who was urine-
ositive was below this plasma cut-off point. Sequential
esting (i.e., applying urinary N-BNP tests for all samples
nd then testing for plasma N-BNP in those with urinary
-BNP 10.7 fmol/ml [37.5% of plasma specimens])
able 3. Binary Logistic Regression Analysis of Various
redictors of Left Ventricular Systolic Dysfunction
B SEM p Value OR
og10 plasma N-BNP 2.345 0.532 0.0005 10.431
og10 urinary N-BNP 1.346 0.286 0.0005 3.843
og10 creatinine 0.580 2.076 NS 0.560
ge 0.005 0.031 NS 1.005
ale gender 1.333 0.537 0.013 3.791
ypertension 0.354 0.557 NS 0.702
iabetes 0.397 0.950 NS 1.487
schemic heart disease 0.870 0.502 NS 2.386
values and odds ratios (OR) are reported for the predictor variables and factors. B
nd SEM refer to the regression coefficient and its standard error.
N-BNP  N-terminal pro-brain natriuretic peptide; NS  not significant.ould achieve rates of detection and echocardiography
N
hsage similar to those in the logistic model or the plasma/
rinary N-BNP product (Table 2).
pplication of tests to high-risk subjects. For those with
history of ischemic heart disease (IHD; n 103, of whom
1 had LVSD), both plasma and urinary N-BNP ROC
urves had reasonable AUCs (0.799 and 0.797, respec-
ively). Another high-risk group would be those 65 years
f age with hypertension or IHD. Of 699 subjects in this
roup, 23 had LVSD. The ROC curves and other data for
lasma and urinary N-BNP, as well as the product of these
wo parameters, are presented in Figure 3 and Table 4.
pecificities and PPVs of the urinary tests are better than
hose of the plasma N-BNP tests, and both are higher than
igure 2. A scatterplot of urinary and plasma N-terminal pro-brain
atriuretic peptide (N-BNP) in those subjects with a positive urine test
defined as 10.7 fmol/ml). Normal subjects (open circles) or subjects
ith left ventricular systolic dysfunction (solid triangles).
igure 3. The receiver-operating characteristic curves for plasma and urinary
-terminal pro-brain natriuretic peptide (N-BNP) and the plasma/urinary
-BNP product in left ventricular systolic dysfunction detection within a
igh-risk group (age 65 years, hypertension, ischemic heart disease).
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he plasma/urinary N-BNP product yielded the highest
pecificities and PPVs, enabling detection of one case of
VSD with about seven scans.
We examined ROC curves for other high-risk groups in
hom an echocardiogram was warranted (such as various
ombinations of the presence of IHD, hypertension, diabetes
ellitus, LVH, AF, or valve disease) (Table 5) and compared
hem with the remainder of the population (in whom there
as no a priori reason for an echocardiogram). The ROC
reas and specificities for urine or plasma N-BNP in both
he population in whom echocardiography was warranted
nd in those with no such indication were very similar
Table 5). Urinary N-BNP had better specificities and a
ower number of cases to be scanned than plasma N-BNP in
very population considered. Only slight improvements in
pecificity and the number of cases to be scanned were evident
ith the plasma/urinary N-BNP product.
ost of different screening strategies. We examined the
osts of different screening strategies compared with obtain-
ng echocardiograms for the whole population (strategy A,
able 6). Strategy B (measuring plasma N-BNP in the
hole population and scanning those with positive results)
ad previously been shown to be cost effective (9). Use of
rinary N-BNP (strategy C) saves about one-third of the
ost of strategy B. Further savings are possible by either
sing the plasma/urinary N-BNP product in all patients
strategy D) or testing urinary N-BNP first and then
erforming the plasma N-BNP test on the urine-positive
ases (strategy E). In strategy F, G, and H, all patients with
HD or other conditions that would warrant an echocar-
iogram are scanned, and urinary N-BNP tests applied to
he remainder. All these strategies are actually more costly
han performing urinary N-BNP tests on the whole popu-
ation, mainly because only 4% to 10.7% of the group who
arrant a scan had LVSD, and echocardiography is rela-
ively more expensive than the N-BNP test (Table 5).
etection of other cardiac abnormalities in those with
reserved systolic function. Other cardiac abnormalities
n subjects with preserved systolic function (LVWMI 1.8
r LVEF 40%) included AF (n  14), LVH by ECG
n  115), and occult valvular abnormalities (moderate or
evere mitral regurgitation or aortic stenosis, n  8). Table 7
ocuments the ROC-AUCs for detection of these individ-
al abnormalities, as well as when all were combined.
lasma N-BNP showed significant ROC-AUCs for detec-
ion of AF and valvular abnormalities that were not repli-
ated with urinary N-BNP. Neither test was clinically useful
or detection of LVH. For detection of a combination of
VSD, AF, or valvular abnormalities, both plasma and
rinary N-BNP had significant ROC-AUCs, although
lasma N-BNP performed better than urinary N-BNP.
tability of N-BNP in urine. Urinary N-BNP was stable
or 24 h at room temperature (Fig. 4). However, degrada-
ion was evident within 48 and 72 h of storage at roomtemperature (n  6, p  0.02 by the Bonferroni test forTa
b
P
la
U
ri
P
la (
T
ot
of
9 A
Table 5. ROC-AUCs With 95% CI for Plasma, Urinary, and Plasma  Urinary N-BNP Product for Diagnosis of LVSD in At-Risk Groups (as Defined) and Also in Remainder
of Population Without Risk Factors Indicated
Plasma N-BNP Plasma N-BNP Urinary N-BNP Urinary N-BNP
Plasma  Urine
Product
Plasma  Urine
Product
At-Risk
Group
Number With
LVSD/Total
in Group
(%)
Number With
LVSD/Remainder
of Population
(%)
ROC-AUC for
At-Risk Group
(95% CI)
[Specificity %]
{NNTS}
ROC-AUC for
Remainder of
Population
(95% CI)
[Specificity %]
{NNTS}
ROC-AUC for
At-Risk Group
(95% CI)
[Specificity %]
[NNTS]
ROC-AUC for
Remainder of
Population
(95% CI)
[Specificity %]
{NNTS}
ROC-AUC for
At-Risk Group
(95% CI)
[Specificity %]
{NNTS}
ROC-AUC for
Remainder of
Population
(95% CI)
[Specificity %]
{NNTS}
Angina or MI 11/103 (10.7) 17/1,205 (1.4) 0.799 (0.658–0.941)
[27.2]
{7.5}
0.809 (0.692–0.926)
[28.7]
{50.5}
0.797 (0.707–0.888)
[60.9]
{4.0}
0.830 (0.778–0.883)
[64.8]
{24.9}
0.865 (0.789–0.940)
[66.3]
{3.5}
0.911 (0.864–0.956)
[66.2]
{23.9}
Angina, MI,
hypertension,
diabetes
15/393 (3.8) 13/915 (1.4) 0.766 (0.649–0.882)
[28.0]
{20.2}
0.866 (0.735–0.997)
[31.3]
{52.4}
0.836 (0.784–0.888)
[67.7]
{9.1}
0.829 (0.763–0.895)
[64.0]
{27.5}
0.907 (0.865–0.949)
[77.8]
{6.2}
0.922 (0.867–0.978)
[64.4]
{27.2}
Angina, MI,
hypertension,
diabetes,
LVH, AF,
valve disease
19/474 (4) 9/834 (1.1) 0.772 (0.664–0.880)
[29.2]
{18.6}
0.871 (0.703–1.0)
[32.2]
{70.7}
0.846 (0.799–0.893)
[66.8]
{8.7}
0.804 (0.725–0.882)
[64.4]
{37.1}
0.913 (0.876–0.950)
[77.8]
{5.9}
0.912 (0.841–0.984)
[65.7]
{35.8}
Specificities for diagnosis of systolic heart failure at sensitivities of 92.3% to 94.7% sensitivities are reported in [brackets]. At this level of sensitivity, one case of LVSD will be missed. The number needed to scan (NNTS) to detect one
case of LVSD is reported in {brackets}.
AF  atrial fibrillation; LVH  left ventricular hypertrophy; MI  myocardial infarction; other abbreviations as in Tables 1 and 2.
Table 6. A Number of Different Strategies for Screening Are Analyzed for the Total Number of Scans and N-BNP Tests Resulting From the Screening
Strategy
Initial Echo
Scans
Plasma or Urinary
N-BNP Tests ECGs
Echo Scans
Resulting From
Positive N-BNP
Tests
Total
Echo Scans
Cost of
Echo
($)
Cost of
N-BNP
Tests
($)
ECG Costs
($)
Total Cost
($)
Cost/1,000
Subjects
($)
Cost to Detect
One Case of
LVSD
($)
A 1,308 1,308 549,360 0 0 549,360 420,000 15,555
B 1,308 783 783 328,860 41,856 0 370,716 283,422 10,497
C 1,308 447 447 187,740 41,856 0 229,596 175,532 6,501
D 2,616 308 308 129,360 83,712 0 213,072 162,899 6,033
E 1,798 291 291 122,220 57,536 0 179,756 137,428 5,089
F 103 1,205 434 537 225,540 38,560 0 264,100 201,911 7,478
G 393 915 338 731 307,020 29,280 0 336,300 257,110 9,522
H 474 834 915 303 777 326,340 26,688 27,450 380,478 290,885 10,773
Strategies: A  scan all patients; B  plasma N-BNP tests in all patients and scan the positive tests; C  urinary N-BNP tests in all patients and scan the positive tests; D  plasma and urinary N-BNP tests in all patients and scan
the positive tests; E  urinary N-BNP tests in all patients and plasma N-BNP in urine-positive cases, then scan the positive tests from sequential plasma testing; F  scan all ischemic heart disease (IHD) patients and urinary N-BNP
in remainder, then scan the positive tests; G  scan all IHD, hypertensive (HT), and diabetic (DM) patients and urinary N-BNP in remainder, then scan the positive tests; H  scan all IHD, HT, DM, AF, LVH, valve lesion patients
and urinary N-BNP in remainder, then scan the positive tests.
ECG  electrocardiogram; other abbreviations as in Tables 1 and 2.
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vidence of degradation.
ISCUSSION
his prospective study assessed the utility of urinary and
lasma N-BNP for community screening of previously undi-
gnosed LVSD. Urinary N-BNP was only detectable in 45.8%
f the population, which included all cases of LVSD. The
ource of urinary N-BNP is unknown, although as a small
olecule (8 kd), it is likely to be filtered through the
lomerulus. It is possible that the filtered or secreted peptide
ould be either partially degraded or reabsorbed within the
enal tubules, leading to a lack of correlation between filtered
oad of N-BNP and measured urinary N-BNP. Our previous
tudy on hospitalized patients with New York Heart Associ-
tion functional class IV heart failure (6) who had very high
lasma and urinary N-BNP levels demonstrated a modest
orrelation between urinary and plasma N-BNP. This finding
as not confirmed in the present study involving less symp-
omatic patients who had lower plasma and urinary N-BNP
alues. Totsune et al. (9) reported increased urinary excretion
f BNP in patients with impaired renal function. In vitro, renal
ubule cells may produce BNP (7). Taken in conjunction with
ur findings, urinary N-BNP may reflect both filtered plasma
-BNP (produced from the myocardium) and renally pro-
uced N-BNP. The latter may be a surrogate marker of
able 7. ROC-AUCs for Detection of Other Cardiac Abnormal
Combined Group Comprising Those With Atrial Fibrillation,
ot Mutually Exclusive)
Number R
ther cardiac abnormalities with preserved
systolic function
AF 14
ECG LVH 115
Valvular abnormalities 8
Combined (AF, LVH, valvular abnormalities) 133
VSD, AF, or valvular abnormalities 50
F  atrial fibrillation; ECG  electrocardiographic; LVH  left ventricular hypep
igure 4. Stability of urinary N-terminal pro-brain natriuretic peptide
N-BNP) when stored at room temperature for up to 72 h.ystolic dysfunction, although the actual mechanisms regulat-
ng renal N-BNP production need to be further investigated.
or example, volume loading may lead to increased urinary
-BNP excretion (10).
Urinary N-BNP performs as well as plasma N-BNP for
xcluding LVSD. The specificities we report are similar to those
n the literature (3,4). Due to its higher specificity and PPV, the
umber of positive cases subsequently requiring echocardiography
s less than that if plasma N-BNP were employed as the first
nvestigation. The reasons for the improved performance of
rinary compared with plasma N-BNP include the lack of a
elationship with age, gender, or heart rate.
Ease of urine sampling without the need to consider age-
nd gender-dependent normal ranges are advantages rele-
ant to consider in a screening program. Our present data
n urinary N-BNP suggest it is stable for 24 h at room
emperature, although prolonged storage at room tempera-
ure leads to degradation. It is therefore recommended that
oth urine and plasma specimens be frozen within 24 h of
ollection for analysis.
Both urinary and plasma N-BNP have an independent
redictive value for LVSD detection in logistic modeling. A
imilar outcome could be obtained by the plasma/urinary
-BNP product. However, the most cost-effective strategy
ould be to apply these tests sequentially, using the urinary
-BNP test first to rule out LVSD and then subjecting the
rine-positive cases to plasma testing. This minimizes the
umber of assays needed but achieves similar specificity,
PV, NPV, and number of scans to detect one LVSD case
s testing both specimens in all subjects.
It has previously been concluded that screening with
lasma BNP has a cost-effectiveness similar to other ac-
epted health interventions ($50,000 per quality of life
djusted year gained), provided the prevalence of LVSD
xceeds 1% of the population (8). Based purely on the cost
f the screening program, testing urinary N-BNP with or
ithout the plasma N-BNP may be less costly than a
rogram based on plasma N-BNP alone. Focusing on
igh-risk groups was not cost-effective.
When detection of other cardiac abnormalities in those with
n Those With Preserved Systolic Function and in
lar Abnormalities, and LVSD (These Diagnoses Are
a N-BNP
UC (SEM) p Value
Urinary N-BNP
ROC-AUC (SEM) p Value
7 (0.065) 0.0005 0.586 (0.064) NS
1 (0.028) 0.0005 0.553 (0.029) NS
6 (0.056) 0.001 0.401 (0.075) NS
4 (0.027) 0.0005 0.549 (0.026) NS
9 (0.031) 0.0005 0.693 (0.034) 0.0005
; SEM  standard error of mean; other abbreviations as in Tables 1 and 2.ities i
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Screening for Heart Failure Using Urine N-BNP April 5, 2005:1043–50erformed better than urinary N-BNP. This may perhaps
elate to more severe systemic or renal disturbance in LVSD
with the kidneys a possible source of N-BNP) than in AF or
alve disease. These tests are therefore more specific for systolic
ysfunction than other cardiac abnormalities.
tudy limitations. The validity of our findings in other
opulations remains to be established. In particular, the
alue of urinary and plasma N-BNP in larger groups of
igh-risk subjects, as well as in ethnic minorities, should be
xamined. As with any screening study, we could not
pproach subjects who declined the offer of screening to
xamine reasons for their refusal.
onclusions. In this community cohort, both plasma and
rinary N-BNP are effective at excluding the presence of
VSD, with urinary N-BNP exhibiting a higher specificity.
he plasma/urinary N-BNP product further enhances the
pecificity and PPV of LVSD diagnosis. However, sequen-
ial testing (urine, followed by plasma N-BNP in the
rine-positive cases) is likely to achieve similar specificity
hile limiting the number of echocardiograms and the total
umber of N-BNP measurements.
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